


PHARMACEUTICAL 2019

Provention Bio Inc. Rank 170 of 371





PHARMACEUTICAL 2019

Provention Bio Inc. Rank 170 of 371

The relative strengths and weaknesses of Provention Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Provention Bio Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 4,057% points. The greatest weakness of Provention Bio Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 156% points.

The company's Economic Capital Ratio, given in the ranking table, is -132%, being 199% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,871
Liabilities, Non-Current	0
Other Assets	61,529
Other Compr. Net Income	0
Other Expenses	333
Other Liabilities	0
Other Net Income	669
Property and Equipment	0
Research and Development	22,649
Revenues	0
Selling, General and Administrative Expense	4,165

Output Variable	Value in 1000 USD
Assets	61,529
Liabilities	1,871
Expenses	27,147
Stockholders Equity	59,658
Net Income	-26,478
Comprehensive Net Income	-26,478
Economic Capital Ratio	-132%